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Abstract
The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on
Adrenoceptors [58], see also [180].
Adrenoceptors, α1
α1-Adrenoceptors are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline.
phenylephrine, methoxamine and cirazoline are agonists and prazosin and cirazoline antagonists considered
selective for α1- relative to α2-adrenoceptors. [3H]prazosin and [125I]HEAT (BE2254) are relatively selective
radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin
(Bodipy PLprazosin- QAPB) are used to examine cellular localisation of α1-adrenoceptors. Selective α1-
adrenoceptor agonists are used as nasal decongestants; antagonists to treat hypertension (doxazosin, prazosin)
and benign prostatic hyperplasia (alfuzosin, tamsulosin). The α1- and β2-adrenoceptor antagonist carvedilol is
used to treat congestive heart failure, although the contribution of α1-adrenoceptor blockade to the therapeutic
effect is unclear. Several anti-depressants and anti-psychotic drugs are α1-adrenoceptor antagonists
contributing to side effects such as orthostatic hypotension and extrapyramidal effects.
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Adrenoceptors, α2 
α2-Adrenoceptors are activated by (-)-adrenaline and with lower potency by (-)-noradrenaline. brimonidine and
talipexole are agonists and rauwolscine and yohimbine antagonists selective for α2- relative to α1-
adrenoceptors. [3H]rauwolscine, [3H]brimonidine and [3H]RX821002 are relatively selective radioligands. There
is species variation in the pharmacology of the α2A-adrenoceptor. Multiple mutations of α2-adrenoceptors have
been described, some associated with alterations in function. Presynaptic α2-adrenoceptors regulate many
functions in the nervous system. The α2-adrenoceptor agonists clonidine, guanabenz and brimonidine affect
central baroreflex control (hypotension and bradycardia), induce hypnotic effects and analgesia, and modulate
seizure activity and platelet aggregation. clonidine is an anti-hypertensive and counteracts opioid withdrawal.
dexmedetomidine (also xylazine) is used as a sedative and analgesic in human and veterinary medicine with
sympatholytic and anxiolytic properties. The α2-adrenoceptor antagonist yohimbine has been used to treat
erectile dysfunction and mirtazapine as an anti-depressant. The α2B subtype appears to be involved in
neurotransmission in the spinal cord and α2C in regulating catecholamine release from adrenal chromaffin cells.
Adrenoceptors, β
β-Adrenoceptors are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. Isoprenaline is
selective for β-adrenoceptors relative to α1- and α2-adrenoceptors, while propranolol (pKi 8.2-9.2) and
cyanopindolol (pKi 10.0-11.0) are relatively β1 and β2 adrenoceptor-selective antagonists. (-)-noradrenaline,
xamoterol and (-)-Ro 363 show selectivity for β1- relative to β2-adrenoceptors. Pharmacological differences exist
between human and mouse β3-adrenoceptors, and the 'rodent selective' agonists BRL 37344 and CL316243
have low efficacy at the human β3-adrenoceptor whereas CGP 12177 and L 755507 activate human β3-
adrenoceptors [88]. β3-Adrenoceptors are resistant to blockade by propranolol, but can be blocked by high
concentrations of bupranolol. SR59230A has reasonably high affinity at β3-adrenoceptors, but does not
discriminate well between the three β- subtypes whereas L 755507 is more selective. [125I]-cyanopindolol, [125I]-
hydroxy benzylpindolol and [3H]-alprenolol are high affinity radioligands that label β1- and β2- adrenoceptors and
β3-adrenoceptors can be labelled with higher concentrations (nM) of [125I]-cyanopindolol together with β1- and
β2-adrenoceptor antagonists. [3H]-L-748337 is a β3-selective radioligand [474]. Fluorescent ligands such as
BODIPY-TMR-CGP12177 can be used to track β-adrenoceptors at the cellular level [8]. Somewhat selective β1-
adrenoceptor agonists (denopamine, dobutamine) are used short term to treat cardiogenic shock but,
chronically, reduce survival. β1-Adrenoceptor-preferring antagonists are used to treat hypertension (atenolol,
betaxolol, bisoprolol, metoprolol and nebivolol), cardiac arrhythmias (atenolol, bisoprolol, esmolol) and cardiac
failure (metoprolol, nebivolol). Cardiac failure is also treated with carvedilol that blocks β1- and β2-
adrenoceptors, as well as α1-adrenoceptors. Short (salbutamol, terbutaline) and long (formoterol, salmeterol)
acting β2-adrenoceptor-selective agonists are powerful bronchodilators used to treat respiratory disorders. Many
first generation β-adrenoceptor antagonists (propranolol) block both β1- and β2-adrenoceptors and there are no
β2-adrenoceptor-selective antagonists used therapeutically. The β3-adrenoceptor agonist mirabegron is used to
control overactive bladder syndrome.
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Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current
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